AUSTRALIAN LAUNCH OF ROCHE'S AURORIX

Hoffmann-La Roche's reversible inhibitor of monoamine oxidase type A, Aurorix (moclobemide) has now been launched in Australia. The novel antidepressant product was first launched in Sweden in 1989. It will be marketed in Australia by Roche's local subsidiary, Roche Products.

Moclobemide has been shown to be as effective as tricyclic and 5-HT reuptake inhibitor antidepressants in clinical trials. It is effective against both unipolar and bipolar disorders, agitated and retarded depression and depression associated with psychotic disorders. The product is reportedly safe, even in overdose, which is an important factor given the high rate of suicide in depressed patients.

Because of its specificity of action, moclobemide has a low level of interaction with other compounds, and is therefore useful for the treatment of elderly depressives who are likely to be consuming other medicinal products. Unlike older MAOIs, moclobemide does not interact strongly with tyramine so no dietary restrictions are required. The plasma concentration of moclobemide is increased, however, when cimetidine is concomitantly administered.